VEEV Stock Analysis: Veeva Systems | NYSE
Health Information Services | NYSE, USA | Market Cap: 42.130m USD | 12M Return: -1.1% | US9224751084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 434M
EPS Trend: 97.3%
Qual. Beats: 16
Rev. Trend: 100.0%
Qual. Beats: 11
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Veeva Systems Inc. (NYSE: VEEV) is a U.S.-based cloud software company that serves the global life sciences industry, including pharmaceutical, biotechnology, and consumer products companies. The companys offerings are organized into several cloud platforms: Commercial Cloud (covering CRM, medical content, digital asset management, and analytics), Data Cloud (customer reference data, patient data, and engagement metrics), Development Cloud (clinical trial execution, data management, safety, and regulatory information management), and Quality Cloud. Beyond software subscriptions, Veeva provides implementation, consulting, training, and managed services. Founded in 2007 as Verticals onDemand, it rebranded to Veeva Systems in April 2009, went public in October 2013, and is headquartered in Pleasanton, California. The company operates on a subscription-based SaaS model, which is the standard delivery approach for enterprise software, and its focus on regulated, compliance-heavy workflows (such as clinical trials and regulatory submissions) has made it a specialized vendor within the broader Health Care Technology sub-industry.
- Vault subscription revenue sustains double-digit growth into fiscal 2025
- Pharma R&D budget pressure weighs on Development Cloud bookings
- Data Cloud segment expands with Compass patient analytics adoption
| Net Income: 1.01b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 1.53 > 1.0 |
| NWC/Revenue: 187.7% < 20% (prev 193.4%; Δ -5.68% < -1%) |
| CFO/TA 0.18 > 3% & CFO 1.67b > Net Income 1.01b |
| Net Debt (-7.09b) to EBITDA (1.08b): -6.59 < 3 |
| Current Ratio: 5.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (165.1m) vs 12m ago -1.32% < -2% |
| Gross Margin: 74.89% > 18% (prev 75.59%; Δ -0.70% > 0.5%) |
| Asset Turnover: 40.54% > 50% (prev 37.11%; Δ 3.44% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.72 (Total Current Assets 7.95b - Total Current Liabilities 1.46b) / Total Assets 9.06b |
| B: 0.54 (Retained Earnings 4.90b / Total Assets 9.06b) |
| C: 0.12 (EBIT TTM 1.03b / Avg Total Assets 8.53b) |
| D: 4.56 (Book Value of Equity 7.43b / Total Liabilities 1.63b) |
| Altman-Z'' = 12.07 = AAA |
| DSRI: 1.03 (Receivables 565.6m/472.4m, Revenue 3.46b/2.97b) |
| GMI: 1.01 (GM 75.59% / 74.89%) |
| AQI: 0.92 (AQ_t 0.10 / AQ_t-1 0.11) |
| SGI: 1.17 (Revenue 3.46b / 2.97b) |
| TATA: -0.07 (NI 1.01b - CFO 1.67b) / TA 9.06b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of September 25, 2026, the stock is trading at USD 274.84 with a total of 1,379,866 shares traded. Over the past week, the price has changed by +4.20%, over one month by +10.62%, over three months by +70.34% and over the past year by -1.12%.
Current recommended Stop Loss: 264.40 (which is 3.8% or 1.2 ATR below the current price).
Veeva Systems has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy VEEV.
- StrongBuy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 297.3 | 8.2% |
P/E Trailing = 42.7274
P/E Forward = 28.9855
P/S = 12.1831
P/B = 5.6692
P/EG = 1.1597
Revenue TTM = 3.46b USD
EBIT TTM = 1.03b USD
EBITDA TTM = 1.08b USD
Long Term Debt = 137.1m USD (estimated: total debt 151.7m - short term 14.6m)
Short Term Debt = 14.6m USD (from shortTermDebt, last quarter)
Debt = 151.7m USD (from shortLongTermDebtTotal, last quarter) (leases 151.7m already included)
Net Debt = -7.09b USD (calculated: Debt 151.7m - CCE 7.24b)
Enterprise Value = 35.0b USD (42.1b + Debt 151.7m - CCE 7.24b)
Interest Coverage Ratio = unknown (Ebit TTM 1.03b / Interest Expense TTM 0.0)
EV/FCF = 21.33x (Enterprise Value 35.0b / FCF TTM 1.64b)
FCF Yield = 4.69% (FCF TTM 1.64b / Enterprise Value 35.0b)
FCF Margin = 47.49% (FCF TTM 1.64b / Revenue TTM 3.46b)
Net Margin = 29.34% (Net Income TTM 1.01b / Revenue TTM 3.46b)
Gross Margin = 74.89% ((Revenue TTM 3.46b - Cost of Revenue TTM 868.2m) / Revenue TTM)
Gross Margin QoQ = 75.00% (prev 74.71%)
Tobins Q-Ratio = 3.87 (Enterprise Value 35.0b / Total Assets 9.06b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 151.7m)
Taxrate = 23.55% (312.6m / 1.33b)
NOPAT = 791.1m (EBIT 1.03b * (1 - 23.55%))
Current Ratio = 5.46 (Total Current Assets 7.95b / Total Current Liabilities 1.46b)
Debt / Equity = 0.02 (Debt 151.7m / totalStockholderEquity, last quarter 7.43b)
Debt / EBITDA = -6.59 (Net Debt -7.09b / EBITDA 1.08b)
Debt / FCF = -4.32 (Net Debt -7.09b / FCF TTM 1.64b)
Total Stockholder Equity = 7.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.90% (Net Income 1.01b / Total Assets 9.06b)
RoE = 14.00% (Net Income TTM 1.01b / Total Stockholder Equity 7.25b)
RoCE = 14.01% (EBIT 1.03b / Capital Employed (Equity 7.25b + L.T.Debt 137.1m))
RoIC = 10.63% (NOPAT 791.1m / Invested Capital 7.45b)
WACC = 8.10% (E(42.1b)/V(42.3b) * Re(8.13%) + D(151.7m)/V(42.3b) * Rd(0.0%) * (1-Tc(0.24)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.30 | Cagr: 0.18%
[DCF] Terminal Value 77.97% ; FCFF base≈1.52b ; Y1≈1.74b ; Y5≈2.56b
[DCF] Fair Price = 281.6 (EV 38.5b - Net Debt -7.09b = Equity 45.6b / Shares 161.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.31 | EPS CAGR: 24.64% | SUE: 1.17 | # QB: 16
Revenue Correlation: 99.96 | Revenue CAGR: 15.95% | SUE: 3.23 | # QB: 11
EPS current Quarter (2026-10-31): EPS=2.34 | Chg30d=+2.54% | Revisions=+88% | Analysts=26
EPS current Year (2027-01-31): EPS=9.24 | Chg30d=+1.92% | Revisions=+89% | GrowthEPS=+14.0% | GrowthRev=+15.5%
EPS next Year (2028-01-31): EPS=10.25 | Chg30d=+2.22% | Revisions=+88% | GrowthEPS=+11.0% | GrowthRev=+12.3%
[Analyst] Revisions Ratio: +96% (up=70, down=0)